Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Developments that are changing the treatment of CLL - current and future drugs
Treatment at first relapse in multiple myeloma: how to choose a drug?
Clinical management of venetoclax in multiple myeloma
Current therapy for CLL and the new monoclonal antibody ofatumumab